TGA statutory advisory committees

Statutory advisory committees are established by the Therapeutic Goods Regulations 1990.

The TGA currently has ten statutory advisory committees from which it can obtain independent expert advice on specific scientific and technical matters to aid the TGA's regulatory decision making and other regulatory processes. Further information on each committee is available at the links provided below.

The advice provided by these committees is an important element in the undertaking by the TGA of its regulatory functions. However, it will form only part of the information that is available to, for instance, a TGA delegate making a regulatory decision under the Therapeutic Goods Act. While appropriate consideration will be given to such advice, it is important to note that neither the TGA nor a TGA delegate is obliged to follow it.

It should also be noted that information about advice provided by a committee may not become publicly available until sometime after a committee has provided that advice, for instance through the publication of an AusPAR about a newly registered prescription medicine. However, from 2013 a statement that broadly canvasses the matters considered by the committees at each meeting will be made publicly available within a short period after the meeting.

Committee members are appointed by the Minister and must have expertise in relevant clinical or scientific fields or appropriate consumer issues.

Current committees

Appointments to statutory advisory committees

If you are interested in becoming a member of a TGA statutory advisory committee, please see the following information.

Committees history

In January 2010 an amendment to the Therapeutic Goods Regulations resulted in changes to the names, membership and operation of advisory committees. These changes are contained in Therapeutic Goods Amendment Regulations 2009 No.6.

Information on TGA Committees prior to January 2010 is available in the TGA Internet site archive.

  • Fifty years of independent expert advice on prescription medicines
    This booklet highlights a number of the significant achievements of the ADEC and its successor, the Advisory Committee on Prescription Medicines (ACPM), in facilitating and enabling access to new medicines and in preventing the introduction of medicines that are ineffective or have major safety problems